Long-Acting Glatiramer Depot with Stem Cells for IBD
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for inflammatory bowel disease (IBD) are only partially effective, have serious side effects, and do not cure the disease, with existing treatments like corticosteroids and immunosuppressives offering limited improvement in quality of life for patients.
Innovation Solution
A combination therapy using a long-acting, sustained-release depot form of glatiramer acetate in combination with adipose-derived stem cells, administered parenterally or implanted, to treat IBD, which demonstrates a synergistic effect in reducing disease severity and preventing manifestations such as rectal bleeding and colon shortening.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapies (corticosteroids and immunosuppressives) are administered systemically to treat IBD, then anti-inflammatory effects are achieved, but serious side effects and limited effectiveness occur
Solution Approach 1:
Adipose-derived stem cells serve as an intermediary biological agent that modulates the immune response in IBD. These cells are administered to patients and differentiate into various cell types while secreting anti-inflammatory cytokines, acting as a mediator between the administered therapy and the diseased intestinal tissue, thereby reducing direct exposure to harmful conventional drugs while maintaining therapeutic effectiveness
Solution Approach 2:
The invention combines two distinct therapeutic components: adipose-derived stem cells (biological component) and glatiramer acetate (chemical immunomodulator component). This composite therapy leverages the immunomodulatory properties of both components working synergistically, where stem cells provide long-term immune regulation and glatiramer acetate offers additional anti-inflammatory effects, achieving better outcomes while potentially reducing reliance on harmful conventional therapies
2Reliability
If daily administration of Copolymer 1 is used to treat IBD, then therapeutic effect is achieved, but treatment complexity and patient burden increase
Solution Approach 1:
Adipose-derived stem cells are administered in advance as a one-time or limited-frequency injection that establishes long-term immune modulation. This preliminary action creates a sustained therapeutic effect that reduces or eliminates the need for frequent subsequent administrations, thereby simplifying the overall treatment regimen while maintaining therapeutic effectiveness
Solution Approach 2:
The invention transitions from a static daily injection regimen to a dynamic treatment approach where stem cells are administered less frequently but provide adaptive, long-lasting immune regulation. The stem cells dynamically respond to the inflammatory environment over time, adjusting their immunomodulatory function as needed, thereby achieving sustained therapy with reduced administration frequency
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combined treatment significantly reduces IBD severity and prevents manifestations like rectal bleeding and colon shortening, offering a safer and more effective option compared to traditional therapies, with glatiramer acetate and adipose-derived stem cells administered separately or together to achieve prolonged therapeutic benefits.
Implementation Method 1
Administration of glatiramer acetate shifts the population of T cells from pro-inflammatory Th1 cells to regulatory Th2 cells that suppress the inflammatory response
Implementation Method 2
Given its resemblance to myelin basic protein, glatiramer acetate may also act as a decoy, diverting an autoimmune response against myelin
Implementation Method 3
MSCs can be expanded in vitro and, under appropriate conditions, can give rise to several cell types, including bone and fat precursors. The in vitro-expanded cells have remarkable immunoregulatory properties and effects on tissue repair
Data Source
AI summary
Methods for treating inflammatory bowel disease are provided, comprising administration of glatiramer acetate in a sustained-release depot form and administration of adipose-derived stem cells.